These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21872125)

  • 21. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease.
    Thomassin L; Armengol-Debeir L; Charpentier C; Bridoux V; Koning E; Savoye G; Savoye-Collet C
    World J Gastroenterol; 2017 Jun; 23(23):4285-4292. PubMed ID: 28694669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of infliximab combined with surgery in the treatment of perianal fistulizing Crohn disease].
    Yang BL; Lin Q; Chen HJ; Sun GD; Zhu P; Chen YQ; Gu YF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Apr; 16(4):323-7. PubMed ID: 23608791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and magnetic resonance imaging spectrum of complex perianal fistulizing Crohn's disease: A cohort study from northern India.
    Singh A; Kakkar C; Garg S; Arora K; Midha V; Mahajan R; Virk SS; Jain NP; Singh D; Sood K; Tripathi A; Gupta D; Kaushal IG; Galhotra RD; Saggar K; Sood A
    Indian J Gastroenterol; 2023 Oct; 42(5):668-676. PubMed ID: 37548863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: treatment of perianal fistulizing Crohn's disease.
    Rutgeerts P
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():106-10. PubMed ID: 15352905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
    Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D
    Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL; García-Paredes J; Cruz Santamaria DM; Lana R; Ramírez Fernández E; Rodríguez Asteaga E; Díaz-Rubio M
    Rev Esp Enferm Dig; 2002 May; 94(5):269-79. PubMed ID: 12474335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perianal Crohn disease: evaluation of dynamic contrast-enhanced MR imaging as an indicator of disease activity.
    Horsthuis K; Lavini C; Bipat S; Stokkers PC; Stoker J
    Radiology; 2009 May; 251(2):380-7. PubMed ID: 19401571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed.
    Menachem Y; Avidan B; Lavy A; Lang A; Bardan E; Fidder H; Bar-Meir S; Chowers Y
    Digestion; 2005; 72(2-3):124-8. PubMed ID: 16172549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A
    Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.
    Gelbmann CM; Rogler G; Gross V; Gierend M; Bregenzer N; Andus T; Schölmerich J
    Am J Gastroenterol; 2002 Jun; 97(6):1438-45. PubMed ID: 12094862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
    Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA
    Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab in drug-naïve patients with failed ileorectal anastomosis for Crohn's disease: a new chance for sparing the rectum?
    Sciaudone G; Pellino G; Riegler G; Selvaggi F
    Eur Surg Res; 2011; 46(4):163-8. PubMed ID: 21454983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: medical, surgical and radiological management of perianal Crohn's fistulas.
    Tozer PJ; Burling D; Gupta A; Phillips RK; Hart AL
    Aliment Pharmacol Ther; 2011 Jan; 33(1):5-22. PubMed ID: 21083581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.
    Lönnkvist MH; Theodorsson E; Holst M; Ljung T; Hellström PM
    Scand J Gastroenterol; 2011 Apr; 46(4):420-7. PubMed ID: 21114432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
    Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.